;PMID: 3295562
;source_file_797.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:42..121] = [t:42..121]
;2)section:[e:125..218] = [t:125..218]
;3)sentence:[e:222..342] = [t:222..342]
;4)sentence:[e:343..612] = [t:343..612]
;5)sentence:[e:614..829] = [t:614..829]
;6)sentence:[e:830..950] = [t:830..950]
;7)sentence:[e:951..1074] = [t:951..1074]
;8)sentence:[e:1075..1272] = [t:1075..1272]
;9)section:[e:1276..1320] = [t:1276..1320]

;section 0 Span:0..37
;Nature  1987 Jun 4-10;327(6121):430-2
(SEC
  (FRAG (NNP:[0..6] Nature) (CD:[8..12] 1987) (NNP:[13..16] Jun) (LS:[17..18] 4)
        (::[18..19] -) (NN:[19..30] 10;327-LRB-6121) (-RRB-:[30..31] -RRB-)
        (CD:[31..35] :430) (::[35..36] -) (CD:[36..37] 2)))

;sentence 1 Span:42..121
;A point mutation at codon 13 of the N-ras oncogene in myelodysplastic
;syndrome.
;[44..58]:variation-type:"point mutation"
;[62..70]:variation-location:"codon 13"
;[78..83]:gene-rna:"N-ras"
;[96..120]:malignancy:"myelodysplastic syndrome"
(SENT
  (NP-HLN
    (NP (DT:[42..43] A)
      (NML (NN:[44..49] point) (NN:[50..58] mutation)))
    (PP-LOC (IN:[59..61] at)
      (NP
        (NP (NN:[62..67] codon) (CD:[68..70] 13))
        (PP (IN:[71..73] of)
          (NP (DT:[74..77] the) (NN:[78..83] N-ras) (NN:[84..92] oncogene)))))
    (PP (IN:[93..95] in)
      (NP (JJ:[96..111] myelodysplastic) (NN:[112..120] syndrome)))
    (.:[120..121] .)))

;section 2 Span:125..218
;Hirai H, Kobayashi Y, Mano H, Hagiwara K, Maru Y, Omine M, Mizoguchi H,
;Nishida  J, Takaku F.
(SEC
  (FRAG (NNP:[125..130] Hirai) (NNP:[131..132] H) (,:[132..133] ,)
        (NNP:[134..143] Kobayashi) (NNP:[144..145] Y) (,:[145..146] ,)
        (NNP:[147..151] Mano) (NNP:[152..153] H) (,:[153..154] ,)
        (NNP:[155..163] Hagiwara) (NNP:[164..165] K) (,:[165..166] ,)
        (NNP:[167..171] Maru) (NNP:[172..173] Y) (,:[173..174] ,)
        (NNP:[175..180] Omine) (NNP:[181..183] M,) (NNP:[184..193] Mizoguchi)
        (NNP:[194..195] H) (,:[195..196] ,) (NNP:[197..204] Nishida)
        (NNP:[206..208] J,) (NNP:[209..215] Takaku) (NNP:[216..218] F.)))

;sentence 3 Span:222..342
;Patients with a myelodysplastic syndrome (MDS) which has a risk of leukaemic 
;change exhibit a variable clinical course.
;[238..262]:malignancy:"myelodysplastic syndrome"
;[264..267]:malignancy:"MDS"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[222..230] Patients))
      (PP (IN:[231..235] with)
        (NP
          (NP
            (NP (DT:[236..237] a)
               (JJ:[238..253] myelodysplastic) (NN:[254..262] syndrome))
            (NP (-LRB-:[263..264] -LRB-) (NN:[264..267] MDS)
                (-RRB-:[267..268] -RRB-)))
          (SBAR
            (WHNP-1 (WDT:[269..274] which))
            (S
              (NP-SBJ-1 (-NONE-:[274..274] *T*))
              (VP (VBZ:[275..278] has)
                (NP
                  (NP (DT:[279..280] a) (NN:[281..285] risk))
                  (PP (IN:[286..288] of)
                    (NP (JJ:[289..298] leukaemic) (NN:[300..306] change))))))))))
    (VP (VBP:[307..314] exhibit)
      (NP (DT:[315..316] a) (JJ:[317..325] variable) (JJ:[326..334] clinical)
          (NN:[335..341] course)))
    (.:[341..342] .)))

;sentence 4 Span:343..612
;It has been suggested that the  development of leukaemia in patients with MDS
;may be related to chromosomal  abnormalities or genetic alterations: somatic
;mutation of the N-ras gene is now  considered to be a critical step in the
;genetic basis of human leukaemogenesis.
;[390..399]:malignancy:"leukaemia"
;[417..420]:malignancy:"MDS"
;[490..497]:variation-type:"somatic"
;[514..519]:gene-rna:"N-ras"
(SENT
  (S
    (S
      (NP-SBJ-2
        (NP (PRP:[343..345] It))
        (SBAR-3 (-NONE-:[345..345] *EXP*)))
      (VP (VBZ:[346..349] has)
        (VP (VBN:[350..354] been)
          (VP (VBN:[355..364] suggested)
            (NP-2 (-NONE-:[364..364] *))
            (SBAR-3 (IN:[365..369] that)
              (S
                (NP-SBJ-4
                  (NP (DT:[370..373] the) (NN:[375..386] development))
                  (PP (IN:[387..389] of)
                    (NP (NN:[390..399] leukaemia)))
                  (PP-LOC (IN:[400..402] in)
                    (NP
                      (NP (NNS:[403..411] patients))
                      (PP (IN:[412..416] with)
                        (NP (NN:[417..420] MDS))))))
                (VP (MD:[421..424] may)
                  (VP (VB:[425..427] be)
                    (VP (JJ:[428..435] related)
                      (NP-4 (-NONE-:[435..435] *))
                      (PP-CLR (TO:[436..438] to)
                        (NP
                          (NP (JJ:[439..450] chromosomal)
                              (NNS:[452..465] abnormalities))
                          (CC:[466..468] or)
                          (NP (JJ:[469..476] genetic)
                              (NNS:[477..488] alterations)))))))))
            (::[488..489] :)
            (S-ADV
              (NP-SBJ-1
                (NP (JJ:[490..497] somatic) (NN:[498..506] mutation))
                (PP (IN:[507..509] of)
                  (NP (DT:[510..513] the) (NN:[514..519] N-ras)
                      (NN:[520..524] gene))))
              (VP (VBZ:[525..527] is)
                (ADVP-TMP (RB:[528..531] now))
                (VP (VBN:[533..543] considered)
                  (S
                    (NP-SBJ-1 (-NONE-:[543..543] *))
                    (VP (TO:[544..546] to)
                      (VP (VB:[547..549] be)
                        (NP-PRD
                          (NP (DT:[550..551] a) (JJ:[552..560] critical)
                              (NN:[561..565] step))
                          (PP (IN:[566..568] in)
                            (NP
                              (NP (DT:[569..572] the) (JJ:[573..580] genetic)
                                  (NN:[581..586] basis))
                              (PP (IN:[587..589] of)
                                (NP (JJ:[590..595] human)
                                    (NN:[596..611] leukaemogenesis))))))))))))))))
    (.:[611..612] .)))

;sentence 5 Span:614..829
;Here we report that DNAs of bone-marrow cells from three out of eight
;patients  with MDS contained an activated N-ras oncogene, as detected by an
;in vivo  selection assay in nude mice with transfected NIH 3T3 cells.
;[699..702]:malignancy:"MDS"
;[726..731]:gene-rna:"N-ras"
(SENT
  (S
    (ADVP-LOC (RB:[614..618] Here))
    (NP-SBJ (PRP:[619..621] we))
    (VP (VBP:[622..628] report)
      (SBAR (IN:[629..633] that)
        (S
          (NP-SBJ
            (NP (NNS:[634..638] DNAs))
            (PP (IN:[639..641] of)
              (NP
                (NP
                  (NML (NN:[642..646] bone) (HYPH:[646..647] -)
                       (NN:[647..653] marrow))
                  (NNS:[654..659] cells))
                (PP (IN:[660..664] from)
                  (NP
                    (NP (CD:[665..670] three))
                    (PP (IN:[671..674] out)
                      (PP (IN:[675..677] of)
                        (NP
                          (NP (CD:[678..683] eight) (NNS:[684..692] patients))
                          (PP (IN:[694..698] with)
                            (NP (NN:[699..702] MDS)))))))))))
          (VP (VBD:[703..712] contained)
            (NP (DT:[713..715] an) (JJ:[716..725] activated)
                (NN:[726..731] N-ras) (NN:[732..740] oncogene))
            (,:[740..741] ,)
            (SBAR-ADV (IN:[742..744] as)
              (S
                (NP-SBJ-1 (-NONE-:[744..744] *))
                (VP (VBN:[745..753] detected)
                  (NP-1 (-NONE-:[753..753] *))
                  (PP (IN:[754..756] by)
                    (NP-LGS
                      (NP (DT:[757..759] an)
                        (ADJP (FW:[760..762] in) (FW:[763..767] vivo))
                        (NN:[769..778] selection) (NN:[779..784] assay))
                      (PP-LOC (IN:[785..787] in)
                        (NP
                          (NP (JJ:[788..792] nude) (NNS:[793..797] mice))
                          (PP (IN:[798..802] with)
                            (NP (JJ:[803..814] transfected)
                              (NML (NN:[815..818] NIH) (NN:[819..822] 3T3))
                              (NNS:[823..828] cells))))))))))))))
    (.:[828..829] .)))

;sentence 6 Span:830..950
;Molecular analysis  revealed the same single nucleotide substitution at codon
;13 in all three  transforming N-ras genes.
;[868..898]:variation-type:"single nucleotide substitution"
;[902..910]:variation-location:"codon 13"
;[938..943]:gene-rna:"N-ras"
(SENT
  (S
    (NP-SBJ (JJ:[830..839] Molecular) (NN:[840..848] analysis))
    (VP (VBD:[850..858] revealed)
      (NP
        (NP (DT:[859..862] the) (JJ:[863..867] same)
          
          (NML (JJ:[868..874] single) (NN:[875..885] nucleotide))
          (NN:[886..898] substitution))
        (PP-LOC (IN:[899..901] at)
          (NP (NN:[902..907] codon) (CD:[908..910] 13))))
      (PP (IN:[911..913] in)
        (NP (DT:[914..917] all) (CD:[918..923] three)
            (VBG:[925..937] transforming) (NN:[938..943] N-ras)
            (NNS:[944..949] genes))))
    (.:[949..950] .)))

;sentence 7 Span:951..1074
;Each of the three patients showed a progression of the  disease and a
;resulting leukaemic change within the following year.
;[1007..1014]:malignancy:"disease"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[951..955] Each))
      (PP (IN:[956..958] of)
        (NP (DT:[959..962] the) (CD:[963..968] three) (NNS:[969..977] patients))))
    (VP (VBD:[978..984] showed)
      (NP
        (NP
          (NP (DT:[985..986] a) (NN:[987..998] progression))
          (PP (IN:[999..1001] of)
            (NP (DT:[1002..1005] the) (NN:[1007..1014] disease))))
        (CC:[1015..1018] and)
        (NP (DT:[1019..1020] a) (VBG:[1021..1030] resulting)
            (JJ:[1031..1040] leukaemic) (NN:[1041..1047] change)))
      (PP-TMP (IN:[1048..1054] within)
        (NP (DT:[1055..1058] the) (JJ:[1059..1068] following)
            (NN:[1069..1073] year))))
    (.:[1073..1074] .)))

;sentence 8 Span:1075..1272
;Our  observation of the mutation at codon 13 in leukaemic cell DNAs from all
;three  cases suggests that activation of the N-ras gene is important in the
;development  of leukaemia in some MDS cases.
;[1099..1107]:variation-event:"mutation"
;[1111..1119]:variation-location:"codon 13"
;[1123..1137]:malignancy:"leukaemic cell"
;[1197..1202]:gene-rna:"N-ras"
;[1244..1253]:malignancy:"leukaemia"
;[1262..1265]:malignancy:"MDS"
(SENT
  (S
    (NP-SBJ
      (NP (PRP$:[1075..1078] Our) (NN:[1080..1091] observation))
      (PP (IN:[1092..1094] of)
        (NP
          (NP (DT:[1095..1098] the) (NN:[1099..1107] mutation))
          (PP-LOC (IN:[1108..1110] at)
            (NP (NN:[1111..1116] codon) (CD:[1117..1119] 13)))))
      (PP-LOC (IN:[1120..1122] in)
        (NP
          (NP
            (NML (JJ:[1123..1132] leukaemic) (NN:[1133..1137] cell))
            (NNS:[1138..1142] DNAs))
          (PP (IN:[1143..1147] from)
            (NP (DT:[1148..1151] all) (CD:[1152..1157] three)
                (NNS:[1159..1164] cases))))))
    (VP (VBZ:[1165..1173] suggests)
      (SBAR (IN:[1174..1178] that)
        (S
          (NP-SBJ
            (NP (NN:[1179..1189] activation))
            (PP (IN:[1190..1192] of)
              (NP (DT:[1193..1196] the) (NN:[1197..1202] N-ras)
                  (NN:[1203..1207] gene))))
          (VP (VBZ:[1208..1210] is)
            (ADJP-PRD (JJ:[1211..1220] important))
            (PP (IN:[1221..1223] in)
              (NP
                (NP (DT:[1224..1227] the) (NN:[1228..1239] development))
                (PP (IN:[1241..1243] of)
                  (NP (NN:[1244..1253] leukaemia)))))
            (PP (IN:[1254..1256] in)
              (NP (DT:[1257..1261] some) (NN:[1262..1265] MDS)
                  (NNS:[1266..1271] cases)))))))
    (.:[1271..1272] .)))

;section 9 Span:1276..1320
;PMID: 3295562 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1276..1280] PMID) (::[1280..1281] :) (CD:[1282..1289] 3295562)
        (NN:[1290..1291] -LSB-) (NNP:[1291..1297] PubMed) (::[1298..1299] -)
        (NN:[1300..1307] indexed) (IN:[1308..1311] for)
        (NNP:[1312..1320] MEDLINE-RSB-)))
